Pricing
  1. US-listed companies
  2. Panbela Therapeutics, Inc.
  3. Financials
  4. Stock-based compensation

Panbela Therapeutics, Inc.【PBLA】

Market cap
$63.36K
P/E ratio
SummaryFinancials
Period EndStock-based compensation (Million USD)YoY (%)
Dec 31, 20231-24.36%
Dec 31, 20221-15.46%
Dec 31, 20211+6.80%
Dec 31, 20201+10.25%
Dec 31, 20191-14.54%
Dec 31, 20181-26.20%
Dec 31, 20172+92.13%
Dec 31, 20161-7.58%
Dec 31, 20151+162566.67%
Dec 31, 20130+0.00%
Dec 31, 20120

Income Statement

RevenueRevenue growth (%)Cost of revenueGross profitGross margin (%)Research & developmentSelling, general & administrativeOperating margin (%)Operating expenses Operating income Income before tax Pretax margin (%)Provision for income taxesEffective tax rate (%)Net income Net income margin (%)Earnings per shareDiluted EPSDividend payout ratio (%)Dividend per shareEBITDAEBITDA margin (%)

Balance Sheet

Cash and cash equivalents Marketable securities, current Total cash & short-term investmentsAccounts receivable, netInventoriesTotal current assetsProperty, plant and equipment, netMarketable securities, non-current Total non-current assetsTotal assets Accounts payableShort-term debtLong-term debt, current Total current liabilitiesLong-term debt, non-current Total non-current liabilitiesTotal liabilities Common stock and paid-in capital Retained earningsStockholders' equityTotal debtNet debtD/E ratio (%)Working capital

Cash Flow

Depreciation & amortizationStock-based compensationCash from operations Capital expendituresCash from investing Payments for dividends Repurchases of common stockProceeds from issuance of term debt, netRepayments of term debtCash from financing Free cash flowFCF margin (%)